|
|
Vaccine Detail
|
hMART-IT |
| Vaccine Information |
- Vaccine Name: hMART-IT
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007613
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Antigen: MART-1 (hMART-IT)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Induces protective antimelanoma immunity in a B16F10 transplantable mouse model (Tanaka et al., 2011).
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Although histological analysis demonstrated diffuse infiltration of CD4(+) T cells and CD8(+) T cells, no reduction of regulatory T cells was observed, suggesting that hMART-IT cannot prevent immunotolerance in the tumor microenvironment (Tanaka et al., 2011).
|
| References |
Tanaka et al., 2011: Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene therapy. 2011; 18(8); 827-834. [PubMed: 21390072].
|
|
